# Nalmefene Gambling Study: Study of Nalmefene HCl in the Treatment of Pathological Gambling

> **NCT00132119** · PHASE2,PHASE3 · COMPLETED · sponsor: **Somaxon Pharmaceuticals** · enrollment: 233 (actual)

## Conditions studied

- Pathological Gambling

## Interventions

- **DRUG:** nalmefene HCl
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00132119
- **Lead sponsor:** Somaxon Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2006-08
- **Final completion:** 2006-08
- **Target enrollment:** 233 (ACTUAL)
- **Last updated:** 2008-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00132119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00132119, "Nalmefene Gambling Study: Study of Nalmefene HCl in the Treatment of Pathological Gambling". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT00132119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*